Technology Information Law Blog by Charles Gideon Korrell

Tag: CAFC

  • Federal Circuit Upholds Narrow Construction of DDR Holdings’ E-Commerce Patent Claims

    The Federal Circuit recently handed down a decision in DDR Holdings, LLC v. Priceline.com LLC, affirming a lower court’s interpretation of key claim terms in DDR’s U.S. Patent No. 7,818,399 (“’399 patent”). The ruling highlights the importance of claim construction in patent infringement litigation and underscores how courts evaluate intrinsic and extrinsic evidence in determining the scope of patent claims.

    Background: The ’399 Patent and the Dispute

    DDR Holdings sued Priceline.com and Booking.com (collectively, “Priceline”) for patent infringement, alleging that their websites violated DDR’s patented method of generating composite web pages that integrate third-party merchant content while preserving the “look and feel” of a host website. The central dispute in the case revolved around the meaning of the claim terms “merchants” and “commerce object”—both of which were pivotal in determining whether Priceline’s accused websites fell within the scope of DDR’s patent.

    After years of litigation, including a stay for inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB), the district court ruled in favor of Priceline, adopting a narrower construction of both disputed terms. DDR appealed, arguing that the lower court had improperly limited the claims.

    Key Patent Law Issues Addressed

    1. Claim Construction and Intrinsic Evidence

    The Federal Circuit reaffirmed its approach to claim construction under Phillips v. AWH Corp., holding that claim terms should be interpreted in light of their plain and ordinary meaning within the context of the patent specification and prosecution history. The court rejected DDR’s argument that the term “merchants” should encompass providers of both goods and services.

    A key factor in this decision was that while DDR’s provisional application mentioned merchants as providers of “products or services,” the final patent specification referred only to merchants as providers of “goods.” The court found that this omission of “services” was deliberate and indicative of the applicant’s intent to exclude services from the claim scope.

    2. The Role of Provisional Applications in Claim Interpretation

    DDR argued that because the provisional application defined merchants as providers of both goods and services, the final patent should be read the same way. The court rejected this argument, emphasizing that a provisional application does not override changes made in the final patent specification. The court cited MPHJ Technology v. Ricoh Americas, where a similar omission from a provisional to a final patent was deemed significant in limiting claim scope.

    3. Deference to the Patent Trial and Appeal Board (PTAB)

    During the IPR, the PTAB had construed “merchants” more broadly, finding that the term could include service providers. DDR attempted to use this as collateral estoppel against Priceline, arguing that the issue had already been decided. However, the Federal Circuit rejected this argument, noting that the PTAB applies a different claim construction standard—the “broadest reasonable interpretation”—whereas courts use the more nuanced Phillips standard. This ruling reinforces that district courts and the Federal Circuit are not bound by PTAB claim constructions in later litigation.

    4. Narrow Construction of “Commerce Object”

    The district court also limited the definition of “commerce object” to products (goods) only, rejecting DDR’s argument that the term should include services. The Federal Circuit upheld this decision, reasoning that the patent specification never mentioned commerce objects in the context of services, reinforcing the exclusion of services from the claim scope.

    Implications for Patent Holders

    The DDR Holdings ruling serves as a critical reminder for patent applicants and litigators:

    • Draft Patent Specifications Carefully – Courts will scrutinize changes from a provisional application to a final patent and may interpret omissions as intentional claim scope limitations.
    • Intrinsic Evidence Prevails – The Federal Circuit reaffirmed that claim meaning is primarily determined from the patent specification and prosecution history, with little room for broader interpretations from external sources.
    • IPR Decisions Don’t Control Litigation – Even if the PTAB construes claims broadly during an IPR, that does not prevent a district court from applying a narrower construction under the Phillips framework.

    Conclusion

    The Federal Circuit’s decision in DDR Holdings v. Priceline.com reinforces the importance of precise patent drafting and highlights the challenges patentees face when arguing for broader claim interpretations in court. By affirming the lower court’s narrow construction, the ruling underscores that omissions in a patent specification can significantly limit claim scope, even when broader language appeared in a provisional application.

    For companies involved in e-commerce and software patents, this case serves as a cautionary tale: when defining the scope of an invention, what’s left out of a patent can be just as important as what’s included.

    By Charles Gideon Korrell

  • Federal Circuit Upholds Sanctions for Frivolous Patent Lawsuit in PS Products v. Panther Trading

    The Federal Circuit has affirmed a district court’s sanctions against PS Products (PSP) and its attorney for filing a meritless design patent infringement case, reinforcing courts’ authority to penalize frivolous litigation. The case underscores the importance of proper venue selection, valid infringement claims, and adherence to litigation ethics.

    litigation. The case underscores the importance of proper venue selection, valid infringement claims, and adherence to litigation ethics.

    Case Background: Design Patent for Stun Device

    PS Products owns U.S. Design Patent No. D680,188, which covers a long-spiked electrode for a stun device. In May 2022, PSP sued Panther Trading Co. in the Eastern District of Arkansas, alleging that Panther’s product infringed the D’188 patent.

    However, from the outset, PSP’s case had serious defects:

    • The accused product and the patented design were “plainly dissimilar”, making infringement implausible.
    • PSP filed suit in the wrong venue, citing general venue rules instead of the patent-specific 28 U.S.C. § 1400.
    • Panther provided PSP with a prior art brochure showing a nearly identical design, raising validity concerns.
    • PSP ignored multiple warnings from Panther about the suit’s lack of merit.

    After receiving Panther’s Rule 11 sanctions warning, PSP voluntarily dismissed the case with prejudice—but refused to reimburse Panther’s legal fees.

    Panther then sought:

    1. Attorney fees under 35 U.S.C. § 285 (for exceptional cases).
    2. $100,000 in sanctions under the court’s inherent power (to deter future frivolous lawsuits).

    The district court ruled against PSP, awarding:

    • $43,344.88 in attorney fees and costs under § 285.
    • $25,000 in deterrence sanctions under its inherent authority.

    PSP appealed the sanctions to the Federal Circuit, but the court upheld the ruling.

    Key Patent Law Issues Addressed

    1. Can Courts Impose Sanctions Beyond Attorney Fees in Patent Cases?

    Yes. PSP argued that once a court grants attorney fees under § 285, it cannot impose additional sanctions under its inherent power.

    The Federal Circuit rejected this argument, citing prior cases where courts have:

    • Awarded both attorney fees and Rule 11 sanctions (Eon-Net v. Flagstar Bancorp).
    • Imposed expert witness fees in addition to attorney fees (Takeda v. Mylan).

    Key takeaway: Courts can impose multiple penalties—attorney fees plus additional sanctions—if a party engages in bad faith litigation.

    2. What Constitutes “Bad Faith” in Patent Litigation?

    The district court found PSP acted in bad faith, citing:

    1. Frivolous infringement claim: The designs were “plainly dissimilar”, making the lawsuit objectively unreasonable.
    2. Repeated venue violations: PSP filed 25 lawsuits in Arkansas using incorrect venue rules.
    3. Pattern of meritless filings: PSP dismissed over half of its past cases early, suggesting a litigation abuse strategy.

    The Federal Circuit upheld these findings, emphasizing that courts can infer bad faith from a history of filing meritless lawsuits.

    Key takeaway: A pattern of weak lawsuits can justify sanctions—especially when a party ignores procedural rules.

    3. Can Sanctions Be Imposed if Rule 11 Was Not Formally Triggered?

    Yes. PSP claimed that since Panther never formally filed a Rule 11 motion, sanctions should not apply.

    However, Rule 11 was unavailable because PSP dismissed the case before the 21-day safe harbor period expired. The district court instead used its inherent power to issue sanctions.

    The Federal Circuit ruled this was proper, citing Chambers v. NASCO:

    “When bad faith conduct occurs that cannot be adequately sanctioned under procedural rules, courts may rely on their inherent authority.”

    Key takeaway: Courts can issue sanctions under inherent authority when procedural rules don’t provide an adequate remedy.

    Final Ruling and Implications

    IssueFederal Circuit Decision
    Attorney fees under § 285Affirmed ($43,344.88 awarded)
    Additional sanctions ($25,000)Affirmed—courts can impose both
    Pattern of meritless lawsuitsSupports bad faith finding
    Improper venue claimStrengthened case for sanctions
    Panther’s request for appeal sanctionsDenied—appeal was weak but not “frivolous as argued”

    The Federal Circuit upheld all sanctions, reinforcing courts’ ability to penalize abusive litigation tactics.

    Key Takeaways for Patent Litigants

    1. Repeatedly filing weak lawsuits can backfire.
      • If a pattern emerges, courts can infer bad faith and issue sanctions.
    2. Attorney fees don’t preclude additional penalties.
      • Sanctions under Rule 11 or inherent authority can be stacked on top of § 285 attorney fees.
    3. Ignoring venue rules is risky.
      • Filing in improper venues repeatedly supports sanctions.
    4. Courts can impose sanctions even if Rule 11 is avoided.
      • Voluntarily dismissing a case before a Rule 11 motion is filed won’t necessarily protect against other penalties.
    5. Frivolous design patent claims won’t be tolerated.
      • If two designs are “plainly dissimilar”, infringement claims will likely fail fast.

    For companies dealing with aggressive litigation tactics, this ruling provides a roadmap for defending against and penalizing abusive lawsuits.

  • Federal Circuit Ruling on Crown Packaging v. Belvac: A Lesson in the On-Sale Bar

    On December 10, 2024, the Federal Circuit issued a significant ruling in Crown Packaging Technology, Inc. v. Belvac Production Machinery, Inc., reversing a district court’s decision on patent validity and reinforcing the strength of the on-sale bar under pre-AIA 35 U.S.C. § 102(b). This case highlights the importance of commercial offers for sale and their impact on patent rights.

    Background

    Crown Packaging Technology and CarnaudMetalbox Engineering (collectively, “Crown”) sued Belvac for allegedly infringing U.S. Patent Nos. 9,308,570, 9,968,982, and 10,751,784. These patents cover high-speed, multi-stage necking machines, which are used to shape the tops of metal beverage cans.

    Belvac, in turn, argued that the patents were invalid under the on-sale bar, contending that Crown had offered to sell a machine embodying the patented technology before the critical date—one year before the patent applications were filed.

    The district court ruled in favor of Crown, finding that the cited pre-critical date communications were not commercial offers for sale and that, even if they were, they did not constitute offers made “in this country.” On appeal, Belvac challenged this ruling.

    Key Patent Law Issues

    1. The On-Sale Bar and What Constitutes a Commercial Offer for Sale

    Under pre-AIA § 102(b), a patent is invalid if the invention was on sale in this country more than one year before the patent application was filed. The Supreme Court’s decision in Pfaff v. Wells Electronics, Inc. established that an invention is “on sale” if:

    1. It is the subject of a commercial offer for sale
    2. It is ready for patenting

    Crown did not dispute that the machine was ready for patenting before the critical date. However, it argued that its communications with third parties did not constitute a commercial offer for sale because they were merely quotations and not binding agreements.

    The Federal Circuit disagreed, holding that Crown’s letter to Complete Packaging Machinery in Colorado—which provided a description, price, and delivery terms for its CMB3400 necking machine—was an offer for sale.

    2. When a Quotation Becomes a Binding Offer

    Crown attempted to argue that its “Quotation Number Q22764” was not a formal offer but rather an invitation to negotiate. However, the court found several key elements indicating a definite and binding offer:

    • The letter included a specific price and payment terms (50% upfront, 50% before shipment).
    • It contained detailed delivery terms, specifying the shipment location and timeline.
    • It referenced Crown’s standard conditions of sale, which typically apply to formal purchase agreements.
    • Crown’s own internal order processing records treated similar letters as actual offers that led to binding contracts.

    Because this letter met the standard of a “commercial offer for sale”—one that could be accepted to create a binding contract—the court ruled that the on-sale bar applied.

    3. What It Means for an Offer to Be “In This Country”

    Crown also argued that, even if its letter constituted an offer, it was not an offer “in this country” because the seller (Crown) was based in the UK. The Federal Circuit rejected this argument, citing prior case law (In re Caveney and Hamilton Beach Brands v. Sunbeam Prods.), which established that an offer is “in this country” if it is directed to a U.S. entity at its place of business in the U.S.

    Since Crown’s letter was sent to Complete Packaging Machinery’s Colorado address, it qualified as an offer made in the U.S., regardless of where Crown was located.

    Conclusion: A Cautionary Tale for Patent Owners

    This case serves as a stark reminder that early commercial discussions can jeopardize patent rights. Companies should be cautious when providing detailed price quotes and delivery terms for products that embody their inventions before filing a patent application.

    Key takeaways for patent practitioners and businesses:

    ✔ A detailed price quotation can be an offer for sale.
    ✔ Offers sent to U.S. companies count as being “in this country,” even if sent from abroad.
    ✔ Internal company treatment of pre-sale communications matters—if similar communications have led to orders, they will likely be seen as binding offers.

    By reversing the district court’s decision and finding Crown’s patents invalid, the Federal Circuit reinforced the need for strategic patent filing and commercial restraint to avoid unintentional patent forfeiture.

    Would you like to discuss how this ruling might impact your patent strategy? Drop a comment below!

    By Charles Gideon Korrell

  • Galderma v. Lupin: CAFC Weighs In on ANDA Infringement and the Doctrine of Equivalents

    The Federal Circuit recently affirmed a district court ruling in Galderma Laboratories, L.P. v. Lupin Inc., a patent dispute over the rosacea treatment Oracea®. The decision highlights key issues in Hatch-Waxman litigation, including claim construction, infringement analysis, and the doctrine of equivalents.

    Background: The Patents and ANDA Dispute

    Galderma Laboratories owns patents for Oracea®, medication used to treat rosacea. The formula is designed to release most of the drug immediately (30 mg of the 40 mg total amount) and then the rest later, helping to maintain steady levels in the body.

    Lupin Inc. applied for FDA approval to sell a generic version of Oracea®. Their version had a different mix—22 mg released immediately and 18 mg released later. This led Galderma to sue, claiming that Lupin’s product violated their patents.

    Key Patent Law Issues Addressed

    1. Claim Construction and Functional Limitations

    The court first addressed the proper interpretation of the “immediate-release” and “delayed-release” terms. It affirmed the district court’s functional definitions:

    • Immediate-Release (IR): A portion of the composition that releases doxycycline upon administration without any delayed or extended effect.
    • Delayed-Release (DR): A portion that postpones release through coating or another mechanism.

    This distinction became crucial in determining whether Lupin’s product met the specific claimed composition of 30 mg IR and 10 mg DR doxycycline.

    2. Direct Infringement and ANDA Specification

    Galderma argued that, despite Lupin’s labeling of 22 mg IR and 18 mg DR, a weak enteric coating caused some DR doxycycline to release earlier than intended, effectively creating a 30 mg IR and 10 mg DR composition.

    The court rejected this argument, emphasizing that an ANDA’s formulation specifications are generally dispositive in infringement determinations unless contrary evidence proves otherwise. Lupin’s ANDA stated that its product contained a different IR-to-DR ratio than the claimed composition, and Galderma failed to provide convincing proof of deviation in real-world conditions.

    3. The Role of In Vitro Dissolution Testing

    A key evidentiary dispute involved in vitro dissolution tests showing some doxycycline release at pH 4.5. Galderma argued this indicated Lupin’s DR portion was behaving like an IR portion in vivo.

    The court disagreed, finding that:

    • The pH 4.5 test did not accurately reflect in vivo stomach conditions, where pH levels are typically between 1.0 and 2.0 in fasting conditions.
    • Galderma’s evidence did not establish how many of Lupin’s coated pellets had weak enteric layers or how this would impact overall drug release.
    • Even if some DR doxycycline released at pH 4.5, this did not prove Lupin’s formulation met the claimed 30 mg IR / 10 mg DR composition.

    4. No Infringement Under the Doctrine of Equivalents

    Galderma also argued that Lupin’s formulation was equivalent to the claimed invention under the doctrine of equivalents. The doctrine applies when a product does not literally infringe a patent but performs the same function, in the same way, to achieve the same result.

    The court rejected this argument, stating:

    • The function-way-result test was not met because Galderma failed to show Lupin’s ANDA product functioned identically to Oracea®.
    • The differences between Lupin’s 22 mg IR / 18 mg DR formulation and the claimed 30 mg IR / 10 mg DR formulation were substantial, particularly given the FDA’s strict labeling and bioequivalence standards.

    5. No Indirect or Induced Infringement

    Because there was no direct infringement, the court also ruled out contributory and induced infringement claims against Lupin.

    Final Decision and Impact

    The Federal Circuit affirmed the district court’s ruling, holding that Lupin’s ANDA product does not infringe Galderma’s patents. The decision underscores the importance of ANDA specifications in Hatch-Waxman litigation, the limitations of in vitro testing for proving infringement, and the high bar for applying the doctrine of equivalents in pharmaceutical patent cases.

    This case serves as a reminder that branded pharmaceutical companies must provide clear and convincing evidence when challenging ANDA products—particularly when alleging that small formulation differences amount to patent infringement.

    Post by Charles Gideon Korrell

  • Federal Circuit Ruling in Cytiva v. JSR: A Deep Dive into Patent Obviousness and Inherency in Biotechnology

    In a significant decision for biotechnology and pharmaceutical patents, the Federal Circuit has affirmed-in-part and reversed-in-part the Patent Trial and Appeal Board’s (PTAB) findings in Cytiva BioProcess R&D AB v. JSR Corp.. The case centers around chromatography matrices and protein engineering, with the core dispute being whether certain patent claims were obvious and therefore unpatentable. The ruling provides valuable insight into obviousness determinations, inherency doctrine, and the treatment of unexpected results in patent law.

    Background of the Case

    Chromatography is a key technology used to separate and purify biomolecules, particularly in pharmaceutical manufacturing. The patents at issue cover affinity chromatography matrices that use Protein A (SPA) as a ligand to bind antibodies. Cytiva owns three patents related to modified versions of Domain C of SPA, which were designed to improve stability in alkaline environments—a crucial property for reusability in industrial purification processes.

    JSR challenged Cytiva’s patents via six inter partes reviews (IPRs), arguing that the modifications to Domain C were obvious in light of prior art. The PTAB invalidated 79 claims across Cytiva’s patents but upheld four claims that related to binding properties involving the Fab region of an antibody.

    Both companies appealed:

    • Cytiva argued that the Board incorrectly applied the lead compound analysis and that the Fab-binding properties were unexpected.
    • JSR cross-appealed, asserting that the four surviving claims were also inherently obvious.

    Key Patent Law Issues Addressed

    1. Was the “Lead Compound” Analysis Required?

    Cytiva’s core argument was that the PTAB should have applied the lead compound framework, a two-step analysis commonly used in chemical and pharmaceutical patent cases:

    1. Would a skilled artisan have selected Domain C as a starting point?
    2. Would the prior art suggest modifying Domain C with a reasonable expectation of success?

    Court’s Ruling: Lead Compound Analysis Was Unnecessary

    The Federal Circuit rejected Cytiva’s argument, explaining that the lead compound test is not always required—especially when the prior art explicitly suggests a modification. Here, prior research had already identified five homologous domains (A-E) in SPA, and multiple sources explicitly recommended modifying any of them, including Domain C. Because the modification to improve alkaline stability was already known, no additional justification for selecting Domain C was needed.

    Key Takeaway:

    • The lead compound test is not a mandatory hurdle for proving obviousness—courts may bypass it when prior art already suggests the modification.

    2. Was the Modification to Domain C Obvious?

    Cytiva’s patents claimed a G29A mutation, where glycine at position 29 of Domain C was replaced with alanine. This change had already been made to Domain B in prior art and was known to improve alkaline stability.

    Court’s Ruling: The Modification Was Obvious

    The Federal Circuit affirmed the Board’s decision that making the same G29A mutation in Domain C was obvious because:

    • Prior research had explicitly suggested making this mutation to any SPA domain.
    • All five SPA domains share structural and functional similarities.
    • The motivation for the modification was already well-documented.

    Key Takeaway:

    • If a structural change is well-known in related compounds, and the motivation to apply it exists, it is likely obvious.

    3. Did the Board Properly Apply the Inherency Doctrine?

    Several claims covered chromatography matrices that could bind to the Fab region of an antibody. Cytiva argued that this binding property was unexpected and should count as a secondary consideration of nonobviousness.

    Court’s Ruling: The Fab-Binding Property Was Inherent

    The Federal Circuit sided with JSR, ruling that binding to the Fab part of an antibody was an inherent property of the modified SPA ligands. Since the prior art already disclosed SPA binding to antibodies, the presence of Fab binding was merely a natural consequence—not an inventive step.

    The Court reiterated its precedent from Hospira v. Fresenius Kabi (2020), stating:

    “If a property of a composition is inherent, there is no question of a reasonable expectation of success in achieving it.”

    Thus, the claims that survived at the PTAB were reversed and invalidated.

    Key Takeaway:

    • An inherent property of an otherwise obvious modification does not make an invention patentable, even if that property was unexpected.

    4. Does an Unexpected Result Make an Invention Nonobvious?

    Cytiva argued that unexpected Fab-binding properties should overcome the prima facie case of obviousness.

    Court’s Ruling: Unexpected Results Do Not Overcome Inherency

    While unexpected results can support nonobviousness, the Federal Circuit clarified that this applies only when the unexpected result itself is not inherent. In this case:

    • The SPA ligand naturally binds antibodies.
    • Since Fab-binding was an inherent characteristic, it could not be used to prove nonobviousness.

    The Court distinguished this case from Honeywell v. Mexichem (2017), where an unexpected chemical stability rendered a composition nonobvious. Here, binding to the Fab region was inevitable, making any unexpected results irrelevant.

    Key Takeaway:

    • Unexpected results do not override inherency—they must stem from truly novel aspects of an invention.

    Final Outcome and Impact

    IssueFederal Circuit Decision
    Lead compound analysisNot required when prior art suggests modification
    G29A mutation (Domain C)Obvious because it was recommended in prior research
    Fab-binding propertiesInherent—does not support patentability
    Unexpected resultsCannot override inherency—binding was inevitable

    The Federal Circuit affirmed the invalidation of 79 claims and reversed the PTAB’s decision on four remaining claims, declaring all challenged claims unpatentable.

    Why This Case Matters

    1. Sets Limits on the Lead Compound Analysis
      • If prior art already suggests a modification, courts can skip the lead compound test.
    2. Reinforces the Role of Inherency in Patent Law
      • If an invention inevitably exhibits a property, that property cannot make it nonobvious.
    3. Clarifies When Unexpected Results Matter
      • Unexpected properties must not be inherent to impact nonobviousness.

    For biotechnology and pharmaceutical patent holders, this ruling narrows the path for defending patents based on functional properties or unexpected results. If a claimed invention only refines known modifications, it may face heightened obviousness scrutiny.

    By Charles Gideon Korrell

  • Federal Circuit Affirms Non-Infringement in Mirror Worlds v. Meta: Key Patent Law Takeaways

    On December 4, 2024, the Federal Circuit issued its decision in Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., upholding the district court’s grant of summary judgment in favor of Meta (formerly Facebook) on all claims of patent infringement. The case, involving patents related to time-ordered data streams, raised important issues in patent law, particularly regarding claim construction, infringement, and patent eligibility under 35 U.S.C. § 101.

    Background of the Case

    Mirror Worlds Technologies, LLC alleged that Meta’s News Feed, Timeline, and Activity Log features infringed three of its patents:

    • U.S. Patent No. 6,006,227 (’227 patent)
    • U.S. Patent No. 7,865,538 (’538 patent)
    • U.S. Patent No. 8,255,439 (’439 patent)

    These patents cover methods for organizing and displaying digital information in chronological streams, a system designed to replace traditional folder-based file organization.

    Meta denied infringement and sought summary judgment on multiple grounds, including non-infringement and invalidity under § 101. The district court ruled in Meta’s favor, and Mirror Worlds appealed.

    Key Patent Law Issues Addressed in the Decision

    1. Claim Construction and the “Main Stream” Limitation

    One of the primary disputes in the case revolved around the construction of the term “main stream”, a key feature in the patented system. The patents required that every data unit received or generated by the system be included in the “main stream.” Meta argued, and the court agreed, that its accused systems (Multifeed Leaves and TimelineDB) did not store all received/generated data in a single time-ordered structure, as required by the patents.

    🔹 Court’s Ruling: The Federal Circuit upheld the district court’s finding that some information used by Meta’s systems—such as coefficient scores (which measure user relationships) and advertising data—was received by backend systems but not stored in the alleged “main stream.” This meant that Mirror Worlds could not prove literal infringement.

    🔹 Takeaway for Patent Owners: When drafting claims, precise language matters. If a claim requires that every piece of data be stored in a certain way, an accused infringer only needs to show that one type of data falls outside that structure to avoid infringement.

    2. The “Glance View” Limitation and Non-Infringement of the ’538 and ’439 Patents

    For two of the patents, Mirror Worlds relied on a feature called “glance view”, which required an abbreviated version of a document to be displayed when a user hovered over it. The court ruled that Meta’s accused features did not satisfy this limitation.

    🔹 Court’s Ruling: The district court found that Meta’s contextual dialog boxes (which appear when a user hovers over a link) provided only metadata—such as the source or author of a post—but did not present an actual summary of the document’s content. Because Mirror Worlds failed to present admissible evidence that the accused systems met this limitation, summary judgment was appropriate.

    🔹 Takeaway for Litigants: If a claim includes a specific display requirement, a successful infringement argument requires clear, admissible evidence that the accused product meets that requirement. Unauthenticated screenshots and expert testimony based on them will likely be excluded.

    3. Section 101 Patent Eligibility (Not Addressed)

    Meta cross-appealed the district court’s rejection of its argument that the patents were invalid under Alice Corp. v. CLS Bank Int’l, which governs patent eligibility under 35 U.S.C. § 101. However, because the court affirmed the non-infringement ruling, it declined to address the § 101 issue.

    🔹 Practical Implication: Courts often avoid ruling on patent validity issues when they can resolve a case on infringement grounds. This leaves open questions about whether Mirror Worlds’ patents would have survived a § 101 challenge.

    Final Thoughts: A Cautionary Tale for Patent Holders

    The Federal Circuit’s decision in Mirror Worlds v. Meta reinforces several key lessons for patent owners and litigants:

    1️⃣ Claim precision is critical – If a patent requires that a system include every data unit in a structure, any exception can defeat an infringement claim.
    2️⃣ Evidence matters – Courts will exclude unreliable evidence, such as unauthenticated screenshots, that fail to demonstrate a patent claim is met.
    3️⃣ Patent eligibility remains an open issue – The § 101 challenge was left undecided, but software patents, particularly those covering abstract ideas, continue to face heightened scrutiny.

    For companies developing software-based patents, this case underscores the importance of carefully drafted claims, thorough infringement analysis, and solid evidentiary support when asserting patent rights in court.

    By Charles Gideon Korrell

  • Ericsson v. Lenovo: The Federal Circuit Revisits SEP Licensing and Injunctions

    In a major decision involving standard-essential patents (SEPs) and international licensing disputes, the Federal Circuit vacated a district court’s denial of an antisuit injunction requested by Lenovo against Ericsson. The case revolves around fair, reasonable, and non-discriminatory (FRAND) licensing commitments, the enforcement of foreign patent injunctions, and how U.S. courts handle international patent disputes.

    Background: The SEP Dispute Between Ericsson and Lenovo

    Ericsson and Lenovo both own patents essential to the 5G wireless communication standard, known as SEPs (Standard-Essential Patents). As members of the European Telecommunications Standards Institute (ETSI), both companies have agreed to license their SEPs under FRAND terms, meaning they must negotiate in good faith and offer fair, reasonable, and non-discriminatory licenses.

    When negotiations for a global cross-license between Ericsson and Lenovo failed, both parties initiated legal action:

    • Ericsson sued Lenovo in the U.S., claiming Lenovo was infringing its U.S. 5G SEPs and had breached its FRAND commitment by refusing to negotiate in good faith.
    • Lenovo sued Ericsson in the U.K., asking the British court to determine a fair global licensing rate.
    • Ericsson sought and obtained patent injunctions in Colombia and Brazil, preventing Lenovo from selling products that allegedly infringed Ericsson’s SEPs in those countries.

    In response, Lenovo asked a U.S. court to issue an antisuit injunction, which would block Ericsson from enforcing its foreign patent injunctions. The district court denied Lenovo’s request, and Lenovo appealed to the Federal Circuit.

    Key Patent Law Issues Addressed by the Federal Circuit

    1. Can a U.S. Court Stop a Foreign Patent Injunction?

    Lenovo argued that Ericsson’s FRAND commitment prevented it from seeking SEP-based injunctions in Colombia and Brazil until it had negotiated in good faith. Since the U.S. case was already addressing whether Ericsson complied with its FRAND obligations, Lenovo claimed a U.S. court ruling would resolve the international dispute—meaning an antisuit injunction was justified.

    The Federal Circuit agreed that the district court applied the wrong legal standard in denying Lenovo’s request. It emphasized that a key question was whether the U.S. case would determine if Ericsson’s foreign injunctions were improper under the FRAND framework.

    2. What Does “Dispositive” Mean in Antisuit Injunction Cases?

    For a U.S. court to issue an antisuit injunction, it must find that the domestic case will resolve (or be “dispositive of”) the foreign dispute. The district court held that Lenovo had to prove the U.S. case would definitely result in a global license agreement. The Federal Circuit disagreed, stating that the key issue was whether the U.S. case would determine whether Ericsson could seek foreign patent injunctions—not whether a final license deal would be reached.

    3. SEP Holders and Injunctions: When Are They Allowed?

    A major issue in SEP litigation is when, if ever, an SEP holder can seek an injunction. Lenovo argued that a company making a FRAND commitment should only be allowed to seek an injunction after proving it negotiated in good faith. The Federal Circuit agreed that injunctions should not be allowed unless the SEP holder first fulfills its FRAND obligations.

    This aligns with previous cases, such as Microsoft v. Motorola, where a court stopped an SEP holder from enforcing a German injunction until a U.S. court determined whether it had negotiated a FRAND license properly.

    4. The Role of International Comity

    The decision also addressed whether blocking a foreign injunction would interfere with the authority of courts in Colombia and Brazil. The Federal Circuit emphasized that enforcing contractual FRAND obligations was different from interfering with foreign patent laws. Since Ericsson agreed to global FRAND commitments, a U.S. court could enforce those commitments without overstepping its bounds.

    Outcome and What Comes Next

    The Federal Circuit vacated the district court’s denial of Lenovo’s request for an antisuit injunction and sent the case back for further proceedings. However, this does not mean the antisuit injunction will automatically be granted—rather, the district court must now apply the correct legal framework.

    Why This Case Matters

    This ruling clarifies that:

    • SEP holders like Ericsson must honor their FRAND commitments before seeking injunctions.
    • A U.S. case addressing FRAND compliance can justify blocking foreign patent injunctions.
    • Lenovo v. Ericsson reinforces the Microsoft v. Motorola precedent, affirming that SEPs come with licensing obligations that affect enforcement rights worldwide.

    For companies involved in wireless technology and SEP licensing, this decision is a major development in balancing patent enforcement rights with global licensing obligations. It signals that courts will hold SEP holders accountable for their commitments, limiting their ability to use foreign injunctions as leverage in licensing negotiations.

    Post by Charles Gideon Korrell

  • Federal Circuit Ruling in NexStep v. Comcast: Key Patent Law Takeaways

    On October 24, 2024, the United States Court of Appeals for the Federal Circuit issued a significant decision in NexStep, Inc. v. Comcast Cable Communications, LLC, affirming the district court’s ruling of non-infringement on two patents owned by NexStep. The case raised important questions about claim construction, the doctrine of equivalents, and evidentiary requirements for proving infringement. Below, we break down the key patent law principles addressed by the court.

    1. Claim Construction and the Meaning of “VoIP”

    One of the central disputes in the case revolved around the meaning of “VoIP” (Voice over Internet Protocol) in NexStep’s U.S. Patent No. 8,885,802 (‘802 patent). The court reaffirmed that claim terms must be interpreted as understood by a person skilled in the art at the time of the invention and that industry-standard definitions are crucial when a term is widely recognized.

    • The district court had construed “VoIP” to mean “protocols and data formats for transmitting voice conversations over a packet-switched network, such as the Internet.”
    • NexStep argued for a broader definition that would include any form of audio data transmission.
    • The Federal Circuit affirmed the district court’s narrower definition, holding that the term “VoIP” was well understood in the industry to require two-way voice communication, not just one-way audio transmission.

    Key Takeaway:

    Claim construction remains a critical aspect of patent litigation, and courts rely heavily on technical dictionaries, industry standards, and expert testimony to determine the proper scope of disputed terms.

    2. Doctrine of Equivalents and the “Single Action” Limitation

    The second major issue involved NexStep’s U.S. Patent No. 8,280,009 (‘009 patent), which described a “concierge device” that facilitates technical support sessions through a single user action. NexStep claimed that Comcast’s troubleshooting tools infringed this patent under the doctrine of equivalents, even though Comcast’s system required multiple button presses rather than a single action.

    • The jury initially found no literal infringement but ruled that Comcast’s system infringed under the doctrine of equivalents.
    • However, the district court overturned the jury’s finding, granting judgment as a matter of law (JMOL) for Comcast because NexStep’s expert, Dr. Ted Selker, failed to provide particularized testimony and linking argument showing why multiple actions were equivalent to a “single action.”

    Key Takeaway:

    To succeed under the doctrine of equivalents, patentees must provide specific, well-reasoned testimony explaining how the accused product meets each limitation of the claim in a substantially equivalent way. Generalized assertions of similarity are insufficient.

    3. Evidentiary Burdens in Patent Infringement Cases

    The decision highlights the strict evidentiary requirements needed to establish infringement under the doctrine of equivalents. The court emphasized three key principles:

    1. Element-by-Element Comparison:
      • A plaintiff must prove equivalence for each claim element, not just argue that the overall system is similar.
    2. Particularized Testimony and Linking Argument:
      • The plaintiff’s expert must provide detailed explanations connecting specific features of the accused product to the claimed invention.
    3. Avoiding Generalized Testimony:
      • Simply stating that an accused product functions “in the same way” as the claimed invention without further analysis is insufficient.

    The court concluded that NexStep’s expert testimony was too vague and conclusory to support an infringement verdict under the doctrine of equivalents.

    Key Takeaway:

    Courts are highly skeptical of broad assertions of equivalence without detailed, rigorous evidence. Patent litigants must ensure that their expert testimony is precise, thorough, and directly tied to the claim language.

    Final Thoughts

    The Federal Circuit’s decision in NexStep v. Comcast reinforces the importance of careful claim drafting, precise claim construction, and robust evidentiary standards in proving infringement. The ruling serves as a cautionary tale for patent holders seeking to rely on the doctrine of equivalents—generalized arguments and vague expert testimony will not withstand judicial scrutiny.

    For companies engaged in patent litigation, this case underscores the need to build a strong factual and expert witness foundation to support infringement claims. As courts continue to tighten evidentiary standards, litigants must ensure that their arguments are well-supported, their claim construction is well-reasoned, and their expert testimony is compelling and detailed.

    By Charles Gideon Korrell

  • Federal Circuit Decision in UTTO Inc. v. Metrotech Corp.: Key Takeaways on Patent Law

    The Federal Circuit issued its decision in UTTO Inc. v. Metrotech Corp., a case centered on patent infringement and state-law tort claims. This decision provides significant insights into claim construction, infringement analysis, and the role of economic torts in intellectual property disputes. Below, we explore the key patent law issues addressed by the court.

    Background of the Case

    UTTO Inc. owns U.S. Patent No. 9,086,441 (the ‘441 patent), which covers a method for detecting underground utility lines using GPS technology and predefined buffer zones. UTTO sued Metrotech Corp. for patent infringement, alleging that Metrotech’s RTK-Pro locator device, which features a “walk back” function, infringed its patent. Additionally, UTTO claimed tortious interference with prospective economic advantage under California law.

    The district court dismissed UTTO’s claims, holding that UTTO failed to sufficiently plead infringement and failed to demonstrate an independently wrongful act by Metrotech. UTTO appealed, leading to this decision by the Federal Circuit.

    Claim Construction: Defining “Group of Buried Asset Data Points”

    A central issue in the case was the construction of the term “group of buried asset data points” as used in UTTO’s patent. The district court had determined that this phrase required at least two data points per buried asset, leading to the conclusion that Metrotech’s product, which allegedly used only a single point, did not infringe.

    The Federal Circuit vacated this aspect of the lower court’s ruling, finding that additional claim construction analysis was required. The appellate court noted that while the ordinary meaning of “group” may imply two or more, the specification of the ‘441 patent included references to “one or more buried asset data points.” This raised ambiguity as to whether a single data point could satisfy the claim language. The court remanded the case for further claim construction proceedings.

    Infringement Analysis and the Doctrine of Equivalents

    Beyond claim construction, the Federal Circuit reviewed the district court’s dismissal of UTTO’s infringement claims. The district court had ruled that because Metrotech’s device used only a single data point, it did not infringe the ‘441 patent. Furthermore, the district court rejected UTTO’s doctrine of equivalents argument, which was not challenged on appeal.

    The Federal Circuit emphasized that, depending on the final claim construction, UTTO might still establish infringement. The appellate court’s decision allows UTTO to continue litigating its claims under a broader interpretation of its patent language.

    State-Law Tort Claim: Economic Interference and Antitrust Considerations

    UTTO also alleged that Metrotech engaged in tortious interference with prospective economic advantage by misrepresenting its software capabilities to Honeywell, a potential UTTO customer. UTTO argued that Metrotech falsely claimed it could provide data in a format compatible with UTTO’s software, thereby preventing UTTO from securing a deal with Honeywell.

    The Federal Circuit upheld the district court’s dismissal of this claim, reasoning that UTTO failed to allege an “independently wrongful act.” The court found that Metrotech’s statements did not constitute fraud under California’s Unfair Competition Law. Moreover, UTTO’s antitrust-based argument—that Metrotech unlawfully tied its software to its hardware—failed because UTTO did not adequately allege that Metrotech had market power in the tying-product market.

    Key Takeaways for Patent Litigants

    This decision highlights several important principles in patent litigation:

    1. Claim Construction Matters: The meaning of disputed terms should be carefully argued, particularly when a term’s ordinary meaning conflicts with the patent specification.
    2. Intrinsic and Extrinsic Evidence: Courts will consider intrinsic evidence (the patent’s claims and specification) but may also examine extrinsic evidence (such as expert testimony) when necessary to resolve ambiguity.
    3. Doctrine of Equivalents Limitations: If direct infringement is not established, claimants must present compelling evidence when arguing that an accused product performs substantially the same function in the same way to achieve the same result.
    4. Economic Interference Claims Require Stronger Allegations: Allegations of fraud or anticompetitive conduct must be well-supported with specific factual assertions.

    Conclusion

    The Federal Circuit’s decision in UTTO Inc. v. Metrotech Corp. serves as a crucial reminder of the complexities involved in patent infringement cases and economic tort claims. By remanding the case for further claim construction, the court has provided UTTO another opportunity to argue its infringement case, while reaffirming strict pleading requirements for state-law tort claims. Patent owners and litigants should take note of the importance of precise claim drafting and robust evidence when pursuing intellectual property disputes.

    By Charles Gideon Korrell

  • Court of Appeals Reverses Dismissal in AlexSam v. Aetna: Key Patent Law Issues Explained

    The Federal Circuit’s recent decision in AlexSam, Inc. v. Aetna, Inc. (Case No. 22-2036) highlights critical issues in patent licensing, direct and indirect infringement, and pleading standards in patent litigation. The court vacated and remanded parts of the district court’s dismissal, finding that key errors had been made in assessing AlexSam’s claims against Aetna. Below, we break down the major legal issues addressed in the opinion.

    Background of the Case

    AlexSam, Inc. alleged that Aetna, Inc. infringed U.S. Patent No. 6,000,608 (the ‘608 patent), which covers a multifunction card system used for financial transactions, including medical savings accounts. The lawsuit focused on Aetna’s Mastercard- and VISA-branded products, which AlexSam claimed infringed its patent both directly and indirectly.

    The district court dismissed AlexSam’s claims, finding that Aetna was covered by a prior license agreement with Mastercard and that AlexSam failed to plead sufficient facts to support claims of direct or indirect infringement for the VISA-branded products. The Federal Circuit reviewed these rulings de novo and vacated the district court’s decision in significant respects.

    Key Patent Law Issues Addressed

    1. License Defense in Patent Infringement Cases

    A major issue in the case was whether Aetna’s Mastercard-branded products were covered by a 2005 license agreement between AlexSam and Mastercard. The district court held that all transactions involving Mastercard’s financial network fell within the license’s scope, barring AlexSam’s infringement claims. However, the Federal Circuit found that the district court oversimplified the license agreement.

    • The agreement only covered transactions involving activation or adding value to an account.
    • Not all of the allegedly infringing activities by Aetna’s Mastercard-branded products fell within this scope.
    • Because the patent claims at issue were broader than the license’s scope, some accused transactions might not be licensed.

    As a result, the Federal Circuit vacated the district court’s finding that Aetna was protected by the license agreement, allowing AlexSam’s claims to proceed for further fact-finding.

    2. Direct Infringement: What Constitutes ‘Making’ or ‘Using’ a Patented System?

    AlexSam argued that Aetna directly infringed its patent by making and using the VISA-branded products. The district court dismissed this claim, reasoning that only third-party customers, and not Aetna itself, could have performed the infringing acts.

    The Federal Circuit disagreed, emphasizing that:

    • A complaint does not need to allege infringement on an element-by-element basis but must provide a plausible factual basis for infringement.
    • The complaint plausibly alleged that Aetna controlled and operated the system in a way that constituted making and using the patented invention.
    • The district court erred in resolving disputed factual issues about Aetna’s role at the motion-to-dismiss stage.

    The court reinstated AlexSam’s direct infringement claim, allowing it to proceed to discovery.

    3. Induced and Contributory Infringement: When Is a Party Liable for Third-Party Actions?

    AlexSam also claimed that Aetna induced infringement by instructing and encouraging customers to use its VISA-branded products in an infringing manner. The Federal Circuit found AlexSam’s allegations sufficient to survive dismissal.

    • AlexSam alleged that Aetna provided marketing materials and instructions that led customers to use the products in ways that infringed the ‘608 patent.
    • Aetna had knowledge of the ‘608 patent due to prior notice letters from AlexSam.
    • The allegations plausibly suggested that Aetna’s conduct met the intent requirement for inducement.

    For contributory infringement, the court found that AlexSam plausibly alleged that Aetna provided a Processing Hub, which had no substantial non-infringing uses and was central to the accused system.

    These findings reinforced that indirect infringement claims can survive if they sufficiently allege knowledge, intent, and the absence of substantial non-infringing uses.

    Implications for Patent Holders and Defendants

    The Federal Circuit’s ruling underscores several important principles for patent litigation:

    1. License Scope Matters: Courts will scrutinize whether a license truly covers the accused activities rather than broadly assuming that all transactions are licensed.
    2. Pleading Standards Are Flexible: Patent complaints need not include element-by-element analysis but must provide a plausible basis for infringement claims.
    3. Defendants’ Roles Must Be Factually Assessed: Dismissal is inappropriate when factual disputes exist about a defendant’s control over an infringing system.
    4. Inducement and Contributory Infringement Are Viable Claims: Even without direct infringement by the defendant, liability may arise from instructing or facilitating third-party infringement.

    By clarifying these issues, the Federal Circuit has set the stage for further litigation in the district court, where AlexSam will now have the opportunity to present evidence to support its claims.

    Conclusion

    The AlexSam v. Aetna decision highlights the complexity of patent litigation, particularly in cases involving licensing agreements, direct infringement theories, and allegations of inducement. As the case returns to the district court, it will provide further insight into how courts interpret patent claims in the context of financial and healthcare transaction systems. For patent holders and defendants alike, this ruling is a reminder of the critical role that careful drafting, strategic litigation, and early factual development play in patent cases.

    By Charles Gideon Korrell